Phase II Study of ME3738 prolonged administration in Chronic Hepatitis C patients.
Phase 2
- Conditions
- Chronic Hepatitis C
- Registration Number
- JPRN-jRCT2080221188
- Lead Sponsor
- MEIJI SEIKA KAISHA, LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
The patients who are completed 48 weeks administration for the Phase II Study of ME3738 in Chronic Hepatitis C Patients.
etc.
Exclusion Criteria
- The patients who exihibited some clinically problemed adverse events.
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and Safety
- Secondary Outcome Measures
Name Time Method